Xilio doses first patient in lung cancer trial of XTX501
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.